Biogen Inc. (Nasdaq: BIIB) is pleased to announce the appointment of Adam Keeney, Ph.D., as its new Executive Vice President and Head of Corporate Development. Dr. Keeney will join the company’s Executive Committee, reporting directly to President and Chief Executive Officer Christopher A.
Viehbacher, as of April 17, 2023. His wealth of experience in corporate development will provide invaluable insight in helping Biogen achieve its growth objectives.
Biogen is pleased to announce the appointment of Adam Keeney to its executive leadership team. With a wealth of experience in biopharmaceutical strategy and business development, including the successful completion of numerous value-creating deals, Mr. Keeney is well-positioned to aid Biogen in its quest to achieve sustainable growth.
Under Mr. Viehbacher’s guidance, Mr. Keeney will be responsible for driving the company’s strategy forward and exploring external collaborations and other growth opportunities.
Dr. Keeney has an impressive 20+ year track record in leading R&D, business development and strategy teams at top biotech and pharma companies. Most recently, he was the Chief Executive Officer of NodThera, a clinical stage biotech company with a portfolio of NLRP3 inflammasome inhibitors to treat a variety of inflammatory diseases.
Dr. Keeney brings a wealth of experience to NodThera, having held several high-level business development roles at Sanofi Genzyme, Johnson & Johnson, and H. Lundbeck A/S. Throughout his career, he has been responsible for a range of early and late-stage deals, successfully completing a number of significant transactions. His expertise in therapeutic areas and modalities will be a great asset to NodThera.
Dr. Keeney boasts an impressive academic background, having earned a Ph.D. in Neuropharmacology from the University of Nottingham and a Bachelor of Science in Neuropsychology from the University of Leeds. With this impressive combination of qualifications, Dr. Keeney has established himself as a leader in the field of neuroscience.
For more than 40 years, Biogen has been a leader in biotechnology, shaping the future with groundbreaking innovations to fight neurological and immunological diseases. From the world’s first approved treatment for spinal muscular atrophy to two co-developed treatments targeting Alzheimer’s disease, Biogen has helped countless patients find relief.
And the journey continues with a pipeline of potential new therapies spanning neurology, neuropsychiatry, specialized immunology and rare diseases. With a commitment to serving humanity and a drive to create a healthier, more sustainable and equitable world, Biogen is paving the way for a healthier tomorrow.